Valuation: Evotec

Market Cap 499M 576M 472M 427M 801M 55.23B 807M 5.63B 2.17B 28.01B 2.16B 2.11B 89.32B P/E 2026 *
-2.39x
P/E 2027 * -6.52x
Enterprise Value 642M 741M 607M 549M 1.03B 71.05B 1.04B 7.24B 2.79B 36.03B 2.78B 2.72B 115B EV / Sales 2026 *
1.07x
EV / Sales 2027 * 0.91x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 59 10/06/2024
Change 5-day change 1-year change 3-year change Capi.($)
-78.46%0.00% - - 576M
-0.09%-0.22%-2.19%+26.51% 45.81B
-2.31%-2.94%+350.95%+551.71% 43.91B
+0.07%+4.94%+44.36%+28.82% 44.39B
-0.32%-1.53%+5.63%+65.45% 39.4B
-0.73%-3.06%+9.63%+38.92% 31.26B
+0.20%-8.02% - - 15.75B
-0.53%+5.15%+25.62%+125.74% 17.32B
+0.95%+4.57%+18.42%+34.82% 14.73B
+0.64%-1.91%+80.09%+29.66% 13.03B
Average -8.02%-1.20%+66.56%+112.70% 29.51B
Weighted average by Cap. -0.58%-1.23%+78.29%+134.45%

Financials

2026 *2027 *
Net sales 601M 694M 568M 514M 965M 66.54B 973M 6.78B 2.61B 33.74B 2.61B 2.55B 108B 724M 836M 685M 620M 1.16B 80.19B 1.17B 8.17B 3.14B 40.66B 3.14B 3.07B 130B
Net income -202M -233M -191M -173M -325M -22.37B -327M -2.28B -877M -11.34B -876M -857M -36.17B -48.25M -55.7M -45.63M -41.31M -77.52M -5.34B -78.11M -544M -209M -2.71B -209M -205M -8.64B
Net Debt 143M 165M 135M 122M 230M 15.82B 231M 1.61B 620M 8.02B 619M 606M 25.58B 162M 187M 153M 139M 261M 17.96B 263M 1.83B 704M 9.11B 703M 688M 29.04B
Logo Evotec
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.806EUR
Average target price
4.586EUR
Spread / Average Target
+63.43%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!